{"id":"193382825960-65","name":"Innovative Therapies for Children with Cancer","registrationDate":"2017-03-09T14:15:45.950+01:00","category":3,"subCategory":2,"legal":"Association loi 1901","web":"http://www.itcc-consortium.org/","country":"France","headAddress":"Innovative Therapies for Children with Cancer","headCity":"Villejuif","headPostCode":"94805","headPhone":"(33)1 42 11 60 33","boss":"Gilles Vassal","bossTitle":"Mr","bossPosition":"Pr√©sident","membersCount":2,"membersFTE":"1.25","membership":"http://www.accelerate-platform.eu/&#xd;\nhttps://www.siope.eu/","memberOrga":"ITCC gather more than 50 centres &#xd;\nhttp://www.itcc-consortium.org/itcc-accreditation-quality-committee.php","goal":"ITCC gathers 51 European Paediatric Oncology Departments with expertise in conducting early phase trials in children and adolescents, and 9 European research laboratories.&#xd;<br />The aim of this organisation is to develop novel therapies for the treatment of paediatric and adolescent cancers in cooperation with regulatory bodies, pharmaceutical enterprises, parents and patients.&#xd;<br /> &#xd;<br />In January 2011 ITCC was established as a European Category 1 Network for Paediatric Research at the European Medicines Agency (EnprEMA).&#xd;<br />Its structure comprises several Committees which take care and contribute to a particular issue in the development of novel therapeutic strategies in paediatric oncology","acronym":"ITCC","interests":"Public Health","euInitiatives":"ITCC is a founding member of the Accelerate Platform (http://www.accelerate-platform.eu/) aiming at accelerating innovation for children and adolescents with cancer&#xd;<br />&#xd;<br />The purpose of the ACCELERATE platform is to provide a transparent forum for patients and parents organisations, academic paediatric oncologists and haematologists, pharmaceutical companies and EU regulatory network representatives to discuss, explain and seek ways to address specific overarching issues in promoting to timely improve the outcome of children and adolescents with cancer through the development of innovative anticancer medicines in a timely fashion.","lastUp":"2017-03-09T14:21:53.868+01:00","customers":"","costAbsolu":"","costRange":"","turnoverAbsolu":0,"turnoverRange":""}